A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Type 2 Diabetes

Interventions

DRUG

AZD6370

Oral single doses a+b+c, o.d., suspension

DRUG

AZD6370

Oral single dose, o.d., b.i.d. and q.i.d., suspension

DRUG

Placebo

Trial Locations (3)

Research Site, Linköping

Research Site, Luleå

Research Site, Uppsala